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Introduction
In persons living with HIV, the persistence of intact proviruses 
integrated within host cellular DNA despite long-term antiretro-
BACKGROUND. Persistence of HIV in sanctuary sites despite antiretroviral therapy (ART) presents a barrier to HIV remission 
and may affect neurocognitive function. We assessed HIV persistence in cerebrospinal fluid (CSF) and associations with 
inflammation and neurocognitive performance during long-term ART.
METHODS. Participants enrolled in the AIDS Clinical Trials Group (ACTG) HIV Reservoirs Cohort Study (A5321) underwent 
concurrent lumbar puncture, phlebotomy, and neurocognitive assessment. Cell-associated HIV DNA and HIV RNA (CA-DNA, 
CA-RNA) were measured by quantitative PCR (qPCR). in peripheral blood mononuclear cells (PBMCs) and in cell pellets 
from CSF. In CSF supernatant and blood plasma, cell-free HIV RNA was quantified by qPCR with single copy sensitivity, and 
inflammatory biomarkers were measured by enzyme immunoassay.
RESULTS. Sixty-nine participants (97% male, median age 50 years, CD4 696 cells/mm3, plasma HIV RNA <100 copies/mL) 
were assessed after a median 8.6 years of ART. In CSF, cell-free RNA was detected in 4%, CA-RNA in 9%, and CA-DNA in 48% 
of participants (median level 2.1 copies/103 cells). Detection of cell-free CSF HIV RNA was associated with higher plasma HIV 
RNA (P = 0.007). CSF inflammatory biomarkers did not correlate with HIV persistence measures. Detection of CSF CA-DNA 
HIV was associated with worse neurocognitive outcomes including global deficit score (P = 0.005), even after adjusting for age 
and nadir CD4 count.
CONCLUSION. HIV-infected cells persist in CSF in almost half of individuals on long-term ART, and their detection is 
associated with poorer neurocognitive performance.
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viral therapy (ART) remains a barrier to curing the infection (1). 
While most research has focused on blood CD4+ memory T cells 
as the major viral reservoir, HIV persists in other sites, including 
mucosal lymphoid tissue, bone marrow, and the brain (2–4). HIV 
infects the brain soon after infection and has a number of CNS 
manifestations including HIV-associated neurocognitive disor-
der (HAND), which range in severity from severe HIV-associated 
dementia (HAD) to the more subtle and prevalent mild neuro-
cognitive (MND) and asymptomatic neurocognitive impairment 
(ANI) (5–7). Although neurological complications of HIV have 
been well recognized, questions remain about persistence of virus 
in the CNS that are difficult to address given the inaccessibility of 
brain tissue in living individuals.
Cerebrospinal fluid (CSF) offers a window into neuropatho-
genesis of HIV in living individuals; most prior studies, however, 
have focused on analysis of soluble biomarkers or measurement 
of cell-free HIV RNA in CSF supernatant. Multiple studies have 
revealed persistently abnormal levels of soluble inflammatory 
Results
Characteristics of study participants. Sixty-nine participants with 
HIV (97% male, 71% white) with median age 50 years (range 26 
to 72 years), CD4+ T cell count 696/mm3 (range 240 to 1664), and 
median ART duration of 8.6 years (range 5.4 to 16.4 years) initi-
ated during chronic HIV infection contributed paired CSF and 
blood samples. All had plasma HIV RNA of less than 40 copies/
mL at the time of CSF sampling except 2 participants (with 63 
and 76 copies/mL, respectively). For comparison, paired CSF and 
blood samples were collected from 19 HIV-negative participants 
with a median age of 49 years old, 68% male, and median CD4+ 
T cell count of 770/mm3 (Table 1).
Sixty-five of 69 participants, all with at least 12 years of edu-
cation, participated in a 7-domain neuropsychological test battery 
resulting in a global deficit score (GDS) and total Z score.
Detection of persistent HIV-1 in CSF and blood. HIV DNA 
was detected in CSF cell pellets (centrifuged from ~13 mL CSF) 
in 48% of participants (95% CI: 36%–60%). By contrast, 9% 
(95% CI: 3%–18%) had detectable CSF CA-RNA and only 4% 
(95% CI: 1%–12%) had detectable HIV RNA in 3–5 mL cell-free 
CSF fluid (Figure 1A).
Median levels of detectable CA-DNA in CSF were 2.1 copies/ 
103 (range 0.12–7.00 copies/103) CSF cells. Limiting dilu-
tion analysis of PBMC samples from this study revealed that 
the number of cells assayed for HIV DNA did not affect the 
quantification of HIV DNA (Supplemental Table 1; supple-
mental material available online with this article; https://doi.
org/10.1172/JCI127413DS1). Levels of CA-DNA in PBMCs 
are typically reported per million CD4+ T cells rather than 
per thousand cells, giving a median of 548 copies/106 (range 
0.3–6553 copies/106) CD4+ T cells in the current study. The 
median value of CA-DNA expressed per one thousand CD4+ 
T cells is 0.5 copies, compared with 2.1 CA-DNA copies per 
thousand total cells in CSF. Although comparisons across blood 
fluids containing different cell types is complex, our findings sug-
gest that the frequency of CSF cells containing CA-DNA may be 
similar to or even higher than those in circulating PBMCs. Indeed, 
limiting dilution analysis of PBMCs from a subset of individuals 
in the current study shows that the number of copies of HIV DNA 
detected normalized for cell input was the same or higher in CSF 
cells than in PBMCs (Supplemental Table 1).
Among the 33 participants with detectable 
CSF HIV DNA, 6% and 6% had detectable CSF 
CA-RNA and cell-free HIV RNA, respectively. 
Participants with detectable cell-free HIV RNA in 
CSF had higher levels of plasma HIV RNA by inte-
grase single copy assay (iSCA) than those without 
detectable CSF HIV RNA (median plasma VL, 5.9 
vs <0.4 cps/mL, P = 0.007). By contrast, detection
of CA-DNA in CSF was not associated with HIV 
DNA levels in PBMCs nor with detection of plasma 
HIV RNA by iSCA. Importantly, pre-ART CD4
count (P = 0.27), pre-ART plasma HIV RNA level
(P = 0.15), pre-ART CD4/CD8 ratio (P = 0.09), and 
years of ART at time of lumbar puncture (P = 0.95) 
were not significantly associated with detection of 
CSF HIV DNA (Figure 1, B–E).
molecules in CSF during suppressive ART, as well as correlations 
between CSF inflammation, CSF biomarkers of active neuronal 
injury, and clinical measures of neurocognitive performance, 
supporting the utility of quantitation of CSF biomarkers (8–9). 
Assessment of CSF HIV RNA has been restricted during ART 
since it is often below the limit of standard assays, though there 
are reports of detectable HIV RNA in CSF despite suppression in 
plasma in a minority of asymptomatic individuals, termed asymp-
tomatic CSF HIV escape (10–12). A limited number of studies of 
the cellular component of CSF suggest that CSF cellular profiles 
largely reflect those in the blood (13–15) and that, in untreated  
individuals, HIV DNA may be detected in CSF cells (16–17). To 
what extent HIV persists in CSF cells in people on long-term 
effective ART is uncertain.
In addition to the importance of evaluating HIV in the CSF 
to inform cure research, there are gaps in our knowledge regard-
ing whether HIV persistence is associated with HAND. CNS HIV 
infection can result in impaired neurocognitive performance, 
which manifests as a HAND in 15% to 55% of participants and 
remains a major cause of morbidity in the ART era (6, 18). Although 
the incidence of HAND has decreased with the introduction of 
ART, the milder forms of HAND persist and interfere with daily 
activities (18). As the population with HIV ages, the prevalence 
and severity of HAND are of concern, particularly since there is 
uncertainty around the pathogenesis of the continued neurocog-
nitive decline. The progression of neurologic disease in otherwise 
well-controlled HIV infection has also been studied in the context 
of symptomatic CSF escape in which there is a CSF/plasma HIV 
RNA discordance associated with the development of new neuro-
logic symptoms (19).
To gain further insights into HIV persistence on ART, we 
assayed CSF fluid and cells with sensitive qPCR detection meth-
ods for cell-free HIV RNA and cell-associated HIV DNA and HIV 
RNA (CA-DNA, CA-RNA) and evaluated associations with blood 
HIV measures and soluble CSF biomarkers of immune activation 
in individuals with sustained plasma viral suppression. Clinical 
significance of the laboratory measures was evaluated by neuro-
psychological assessments to examine whether neurocognitive 
performance is associated with the persistence of HIV or inflam-
matory markers in the CSF.
Table 1. Baseline characteristics of study participants
Characteristic HIV+ (n = 69) HIV– (n = 19)
Age, years 50 (45–56) 49 (38-56)
Sex, proportion (% male) 67/69 (97) 13/19 (68)
Duration of ART, years 8.6 (7.4–10.4) --
Blood CD4+ T cell count at lumbar puncture, cells/mm3 696 (502–906) 770 (701–934)
CD4/CD8 ratio at lumbar puncture 1.0 (0.8–1.2) 1.8 (1.4–2.5)
Plasma HIV RNA <40 cps/mL at lumbar puncture, proportion (%)* 67/69 (97) --
CSF WBC, cells/μL 1 (0–2) 1 (0–3)
CSF cell equivalents detected, no. CCR5 copies 7903 (4179–21700) --
CSF/plasma albumin ratio 5.3 (3.8–7.0) 5.0 (3.2–6.8)
*Plasma HIV RNA values in 2 participants with greater than or equal to 40 copies/mL were
63 copies/mL and 76 copies/mL. All values are median and interquartile range (Q1, Q3)  
unless indicated.
biomarkers: negative with IL-6 (Spear-
man = −0.38, P = 0.001), and posi-
tive with CXCL-10 (Spearman = 0.44, 
P <0.001), sCD14 (Spearman = 0.39, 
P = 0.001), and sCD163 (Spearman = 
0.33, P = 0.006). Inflammatory biomark-
ers, especially indicators of myeloid cell 
activation, also correlated between CSF 
and plasma. However, CSF inflamma-
tory biomarkers did not correlate with 
CSF CA-DNA, CA-RNA, or cell-free 
HIV RNA. CSF sCD14 and sCD163 were 
associated with higher levels of plasma 
HIV RNA (r = 0.34, P = 0.004; r = 0.29, 
P = 0.017). CSF CA-DNA and plasma 
inflammatory markers were not statis-
tically associated. Levels of CSF inflam-
matory biomarkers correlated with one 
another and with plasma levels in the 
HIV+ participants, regardless of whether 
they had detected CSF HIV DNA. Higher 
CSF neopterin, CXCL-10, CCL-2, 
sCD14, and sCD163 correlated with 
older age (P ≤ 0.016); higher CSF neop-
terin correlated with lower pre-ART CD4/
CD8 ratio (r = −0.29, P = 0.017; Figure 2, C 
and D, and Supplemental Table 3).
Association between CSF HIV-1 DNA 
and neurocognitive performance. A crit-
ical element of our study was the inclu-
sion of neurocognitive testing to assess 
for relationships between markers of 
HIV persistence and clinical status. The 
median neurocognitive total Z score was 
0.2 (range –1.1–1.5), and median GDS 
was 0.2 (range 0.0–1.3). Detection of 
CSF HIV DNA (versus no detection) was 
significantly associated with poorer neu-
rocognitive total Z score (P = 0.044, Wil-
coxon) and GDS (P = 0.005; Figure 3). 
The association between detectable CSF 
HIV DNA and neurocognitive dysfunc-
tion persisted after adjusting for pre-ART 
CD4 count, current CD4 count and age. 
Fine motor, executive functioning, and 
attention GDS were particularly impact-
ed (data not shown). Soluble biomarkers 
of immune activation in CSF were not 
associated with neurocognitive perfor-
mance (data not shown). Among those 
with no detectable CSF HIV DNA, 4 of 
35 (11%) were clinically impaired while 9 of 30 (30%) with detectable 
CSF HIV DNA were in the clinically impaired range (GDS ≥ 0.5) (20).
Discussion
The striking observation that almost half of participants harbored 
HIV-infected cells in the CSF demonstrates that the CNS compart-
Biomarkers of inflammation and immune activation in CSF and 
blood. Consistent with previous reports, we found that 2 CSF inflam-
matory markers (sCD163 and CXCL-10) were elevated in HIV+ 
versus HIV– participants despite prolonged ART (Figure 2, A and B, 
and Supplemental Table 2). Within HIV+ participants, we observed 
associations between CSF neopterin and other CSF inflammatory 
Figure 1. HIV persistence measures in CSF during ART. In CSF of individuals on sustained ART started  
in chronic infection, cell-free HIV RNA was detected in 4% (95% CI: 1%–12%), CA-HIV RNA was detected in 
9% (95% CI: 3%–18%), and CA-HIV DNA was detected in 48% (95% CI: 36%–60%). The boxes indicate per-
centage positive (A). Detection of CA-HIV DNA in CSF cells did not significantly associate with pre-ART CD4 
count (B), HIV RNA level (C), CD4/CD8 ratio (D), or years on ART (E), where the boxes indicate median values.
of CSF cells in participants on ART who have suppressed plasma 
HIV RNA levels have not been previously performed. Our study 
indicates that examination of CSF cells is important in assessing 
residual HIV in compartments during ART.
We found low rates of detectable HIV RNA in the cell-free CSF 
fraction (4% of samples) and within CSF cell pellets (9% of sam-
ples), suggesting low levels of HIV transcription within cells and 
infrequent release into the extracellular space during systemically 
suppressive ART. A lower rate of detection of HIV RNA in cell-free 
CSF in our study compared with 42% CSF HIV RNA detected by 
iSCA methods in 220 treated individuals in a recent study of CNS 
HIV-1 Antiretroviral Therapy Effects Research (CHARTER) par-
ment is a site of viral persistence despite many years of viremia 
suppression on ART. A recent study showed persistence of HIV 
DNA in CSF cells in 10 of 16 participants after ART suppression 
for a median of 2.6 years, including 2 who started ART during pri-
mary infection (21). Our study now reveals frequent detection of 
HIV DNA in CSF in a larger cohort of individuals (N = 69) who 
initiated ART during chronic infection and were suppressed and 
on ART for a median of 8.6 years. Older studies from the pre-ART 
era using previous PCR techniques have shown that HIV proviral 
DNA could be measured in CSF cells in 68% to 87% of untreated 
individuals, and suggest that a higher proportion of cells may har-
bor HIV DNA in CSF than in PBMCs (16, 22–23). Large studies 
Figure 2. Soluble inflammatory biomarkers in CSF. CSF sCD163 (A) and CXCL-10 (B) were elevated in CSF in HIV+ compared with HIV- participants. Age at 
CSF collection associated with levels of multiple biomarkers including sCD163 (C), and lower pre-ART CD4/CD8 ratio predicted higher CSF neopterin (D). 
Segment inside the box indicates median, box edges represent 25th and 75th percentiles and whiskers 10th and 90th percentiles.
B cells, and NK cells) are believed to originate from the bone mar-
row and presumably reach the CSF via transmigration through 
blood-brain and blood-CSF barriers, or from “drainage” after 
immune surveillance of the brain and meninges, though a recent 
study suggests that CSF contains cells similar to brain-resident 
microglia, suggesting a possible brain origin of a subset of CSF 
cells (29). Our finding that HIV DNA is detected in a large propor-
tion of CSF samples may indicate continuous trafficking of HIV- 
infected cells into the CSF from the periphery, where CA-HIV 
DNA is almost always detectable in CD4+ T cells during ART. 
However, in our study, concentrations of HIV DNA in blood 
CD4+ T cells were not significantly higher in those with HIV DNA 
detected in CSF. An alternative possibility is that CSF CA-HIV 
DNA may reflect release of infected cells into the CSF from the 
brain or meninges, which would suggest previously unrecognized 
sources of persistent HIV.
We cannot accurately compare the quantity of CA-HIV DNA 
in total CSF cells to those in blood CD4+ T cells in the present 
study nor in prior studies of blood or lymph nodes given the dispa-
rate cellular populations assessed. However, our limiting dilution 
assays suggested that quantitation of CA-HIV DNA in CSF was 
not substantially distorted by the low numbers of cells analyzed. 
Given this, the concentration of CA-HIV DNA in CSF samples 
appears to be comparable or higher to levels in PBMCs. The levels 
of CA-HIV DNA in brain tissue during ART are still not well quan-
tified because few brain autopsy samples have been analyzed for 
persistent HIV from individuals who were taking virally suppres-
sive ART or who did not have other confounding health conditions 
at the time of death (30, 31).
Though we have identified HIV-infected CSF cells in a high 
proportion of individuals on effective ART, the significance of this 
HIV DNA detection in relation to a persistent reservoir of replica-
tion-competent HIV in the CNS compartment is unknown. The 
genetic relatedness of cell-associated and cell-free virus in the 
CSF with that in blood has not been characterized. Further, the 
proportion of CA-HIV DNA in CSF cells which is intact or induc-
ible is unknown. The latter is a fundamental unanswered ques-
tion that has major implications for prevention and treatment of 
HIV-associated CNS disease as well as efforts for long-term HIV 
remission. Studies collecting larger CSF volumes to yield enough 
cells or development of novel assays for intact virus that use 
fewer cells may help to answer these important questions.
Previous studies have demonstrated associations between 
HIV persistence and markers of immune activation or inflam-
mation in blood and other tissues (32, 33). Our finding that CSF 
levels of inflammatory biomarkers did not associate with CSF 
measures of HIV persistence is consistent with the lack of asso-
ciation between markers of HIV persistence and immune activa-
tion or inflammation in blood in a prior study of individuals on 
long-term effective ART in the ACTG HIV Reservoirs Cohort 
Study (A5321), from which the current study participants were 
enrolled (34). Though we did find associations between 2 CSF 
markers of myeloid immune activation (sCD14 and sCD163) 
and plasma viremia, in this cohort of continuously virally sup-
pressed individuals, viral persistence does not appear to be 
a main driver of chronic immune activation within compart-
ments, nor is the latter driving viral persistence. Other causes 
ticipants may be due to a number of factors (24). Given the fact 
that our cohort was enrolled and followed long-term within ACTG 
studies with documented viral suppression for numerous visits, 
it is likely that our cohort was more consistently well-suppressed 
than the participants in the CHARTER study who were identified 
by a single plasma HIV RNA less than or equal to 50 copies/mL. 
Participants in our cohort were also more likely to be on their first 
regimen (42% of our study participants versus only 22% of the 
CHARTER study participants), had been on ART for a longer dura-
tion (median 8.6 years in our study versus 5.8 years in the CHAR-
TER study), and started ART at higher CD4 counts (median pre-
ART CD4+ count of 288 cells/mm3 in our study versus 150 cells/
mm3 in the CHARTER study). All of these factors could plausibly 
explain the differences observed between the studies. The lower 
frequency of detection of cell-free HIV-1 RNA in the CSF in our 
study (4%) compared with the CHARTER study (42%) is unlikely 
to be due to differences in assay sensitivity because both assays 
have been validated to 1 copy/mL and similar volumes of CSF were 
assayed (5 mL in the current study versus 2 mL in the CHARTER 
study) (24–26). In addition, 2 prior studies using real-time qPCR 
assays with single copy sensitivity similar to that in the current 
study reported detectable HIV RNA in cell-free CSF supernatant 
at frequencies closer to those observed in our study: 6% to 14% of 
participants had detectable cell-free HIV RNA in CSF during ART 
(27, 28). Taken together, it is likely that differences between the 
CHARTER and current study populations, including the consis-
tency and duration of viral suppression on ART, contributed to the 
lower frequency of detection of cell-free HIV-1 RNA detection in 
CSF reported here.
We do not know the origin of the HIV-infected cells in CSF. 
Mononuclear cells detected in CSF (lymphocytes, monocytes, 
Figure 3. Association between detection of CSF CA-HIV DNA and neuro-
psychological performance. GDS, global deficit score. Segment inside the 
box indicates median, box edges represent 25th and 75th percentiles.
of chronic immune activation and inflammation in HIV infec-
tion during ART could include immune changes and inflam-
mation triggered in pre-ART HIV infection, chronic microbial 
translocation, effects of unrecognized coinfections, or viral per-
sistence in tissues not accessed through the sampled fluids.
Neurocognitive impairment in individuals with HIV is likely 
multifactorial, with potential contributions from a variety of 
etiologies including persistent HIV infection, age, unresolved 
neuro inflammation, and comorbid conditions such as substance 
use, vascular dysfunction, mood disorders, and poor educational 
attainment (35–37). Despite this, we identified a significant asso-
ciation between detectable HIV DNA in CSF cells and neurocog-
nitive performance, revealing potential clinical relevance of this 
viral measure in the CNS. It is possible that persistent HIV in the 
CNS may drive neurocognitive injury, though the mechanisms of 
this are unknown. Alternately, this may indicate a legacy effect, 
in which processes associated with long-term exposure to HIV 
prior to initiation of ART lead to both irreversible neurological 
injury and more extensive infection of cells that persist in CSF. 
Lack of an association with inflammatory biomarkers suggested 
that current inflammation does not lead to present neurocogni-
tive dysfunction, but does not rule out prior inflammation as the 
underlying cause of neuronal injury. These findings underscore 
the potential clinical significance of HIV persistence in the CNS, 
which needs additional evaluation. Although the median neuro-
cognitive performance in both groups in this study was within 
normal limits, 30% of those with detectable CSF CA-HIV DNA 
had neuropsychological performance in the clinically impaired 
range compared with 11% of those without CSF CA-HIV DNA. 
This difference in the rate of impairment between the groups 
implies an increased risk of HAND among those with detectable 
CSF CA-HIV DNA and calls for further investigation into the clin-
ical consequence of persistent HIV in the CNS.
The novelty of the current study centers around its focus on 
measurement of HIV within the cellular component of CSF in par-
ticipants with very long-term and well-documented plasma HIV 
RNA suppression on ART. Prior flow cytometry studies of CSF 
from HIV+ participants have characterized phenotypes of CSF 
immune cells subsets (14, 15). CSF mononuclear cells are primar-
ily composed of T lymphocytes in HIV– individuals and individ-
uals with HIV pre- and post-ART (14). The CD4+ T cell percent-
age ranges from approximately 40% in participants who started 
ART during acute HIV infection to 25% in those who start ART in 
chronic infection (38), and CD4/CD8 ratio measured in blood by 
clinical labs highly correlates with the percentage of CD4+ T lym-
phocytes in CSF (13, 14).
A longitudinal analysis of people with HIV on suppressive 
therapy with both CSF and blood assessments to establish 
whether detection of HIV-infected cells persists over time and 
remains associated with neurocognitive function would add 
weight to our findings. Similarly, assessment of individuals who 
initiated ART during acute infection may be able to address 
questions about the legacy effect of HIV infection. Paradoxical-
ly, detection of HIV in CSF may be higher in those with early 
initiation of ART due to greater preservation of CD4+ T cells 
within the CSF. Additional studies should compare associations 
between ART regimens and the levels of CSF HIV DNA and 
evaluate the longitudinal relationship between HIV persistence 
in CSF and neurocognitive function.
Overall, persistence of HIV in the CNS may represent a barrier 
to optimal neurocognitive function and in addition provide an 
obstacle to the cure for HIV. The sensitive methods of HIV detec-
tion described in the current study, combined with more detailed 
analyses of the proviruses in infected cells found in the CSF, can 
provide new insight into the CNS reservoir of HIV and how best to 
eradicate or control it.
Methods
Study participants and clinical procedures. Individuals with HIV who 
started ART during chronic infection enrolled in the longitudinal 
ACTG HIV Reservoirs Cohort Study (A5321) and consented to an 
optional single cross-sectional lumbar puncture, concurrent blood 
draw, and neuropsychological assessment as part of the approved 
A5321 study protocol. Participants initiated ART during ACTG tri-
als for treatment-naive persons and were followed at least every 6 
months while continuing to receive ART. As a result, clinical data and 
paired plasma and PBMC samples were available from pre-ART study 
visits. In addition, consistent documentation of ART status and HIV 
viral loads was available for these participants from the time of treat-
ment initiation throughout long-term follow-up. A5321 participants 
enrolled in this study had plasma viral suppression (HIV RNA levels 
≤50 copies/mL) starting at week 48 after initiating ART and had sus-
tained viral suppression at follow-up time points (no consecutive HIV 
RNA levels >50 copies/mL); there were no ART interruptions for 21 
days or longer in the 4 years prior to the LP.
CSF and blood samples from HIV– participants of a similar median 
age to the A5321 participants were available from participants in the 
IRB-approved HIV Associated Reservoirs and Comorbidities (HARC) 
study at Yale University for analysis of soluble immune activation bio-
markers for comparison to the HIV samples. These HIV– comparison 
participants were individuals who were recruited from the local New 
Haven community as controls for HIV studies, had no known neuro-
logical conditions, and who participated in blood draw and lumbar 
punctures for research purposes only.
Lumbar punctures were performed using 22 gauge pencil-point 
needles in most cases to withdraw 22 to 25 mL of CSF. CSF samples 
were promptly centrifuged and supernatants and cell pellets stored at 
–80°C according to established ACTG CSF processing protocols.
Laboratory methods. HIV persistence was measured as CA-HIV 
DNA and RNA and cell-free HIV RNA. CA-HIV DNA and RNA were 
measured by qPCR assays in PBMCs and CSF cell pellets derived 
from approximately 13 mL CSF and normalized by amplifiable 
CCR5 cell equivalents using previously described methods (39). 
Cell-free HIV RNA was quantified by iSCA in CSF supernatant (3–5 
mL) and blood plasma (5 mL) (25). By limiting dilution analysis, 
the qPCR assays have been shown to detect 3 copies of HIV-1 DNA 
or RNA standards in 80% to 100% of PCR reactions and 1 copy in 
40% to 70% of reactions, consistent with Poisson probability dis-
tribution for single copy detection (39). Seven inflammatory bio-
markers were measured in cell-free CSF and blood plasma by ELI-
SA (IL-6, CXCL-10, CCL2, sCD14, sCD163, TNF-α [all from R&D 
Systems], and neopterin [GenWay Biotech]).
Neuropsychological assessment. A 7-domain neuropsychological 
test battery was administered to the participants with HIV, assessing 
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